Marie Beylot-Barry
Prof Marie Beylot-Barry is an expert in Dermatology at Centre Hospitalier Universitaire de Bordeaux (France). As of October 2026, ScienceLeadR ranks Marie Beylot-Barry in the top 1% of experts worldwide for Non-Melanoma Skin Neoplasms, Sexually Transmitted Diseases and Lymphoma. Marie Beylot-Barry has authored 729 publications, the most recent in 2026, and is an investigator in 42 clinical trials, 12 of them ongoing. SLR score: 2,444 (community average: 125). How the SLR is computed.
LeadR Profile
Dermatology
Subspecialties: Oncology - Hematology - Immunology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1992 - 2026
Number : 729
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Inflammatory rheumatic diseases under mogamulizumab: a multicenter series of 11 cases. PMID 42858804 — lymphoma, adrenal cortex hormones, arthritis, rheumatic diseases, therapeutics, methotrexate | Joint Bone Spine | 2026 | 0 |
| Cutaneous Lymphoma International Prognostic Index and Risk Stratification in Advanced Mycosis Fungoides and Sézary Syndrome. PMID 42842270 — mycosis fungoides, sezary syndrome, lymphoma, disease progression, skin diseases, diagnosis | JAMA Dermatol | 2026 | 1 |
| Severe oral lichenoid reactions associated with immune checkpoint inhibitors. PMID 42517276 — sexually transmitted diseases, pemetrexed, bevacizumab, skin diseases, immune checkpoint inhibitors, nivolumab, lichen planus, carboplatin | J Eur Acad Dermatol Venereol | 2026 | 0 |
| Durable remission with no survival reduction after mogamulizumab discontinuation in Sézary syndrome. PMID 42490360 — syphilis, sezary syndrome, dermatology | Br J Dermatol | 2026 | 0 |
| Head and neck manifestations associated with hidradenitis suppurativa: A retrospective multicentre study. PMID 42101381 — sexually transmitted diseases, cicatrix, hidradenitis suppurativa, skin diseases, hidradenitis | J Eur Acad Dermatol Venereol | 2026 | 0 |
Clinical Studies 42
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
12 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| FEcal tranSplantation in HidradeniTIs suppuratiVA a piLot Study NCT07668713 — pilot projects, pilots, fecal microbiota transplantation, hidradenitis suppurativa, hidradenitis, therapeutics, transplantation, microbiota | Phase 1 | Not yet recruiting | 2026 |
| Randomized clinical trial to compare oral isotretinoin to standard of care in moderate acne skin of color patients 2023-507519-36-00 — isotretinoin, skin | Phase 3 | Recruiting | 2025 |
| Follow up of a French National Cohort of Patients With Cutaneous Squamous Cell Carcinoma Requiring Systemic Treatment NCT07606508 — skin, cells, carcinoma, squamous cell, neoadjuvant therapy, therapeutics, carcinoma, cutaneous squamous cell carcinoma | N/A | Recruiting | 2021 |
| A Phase 2 Study of PTX 100 Monotherapy in Patients with r r CTCL 2025-521852-45-00 — cells, safety, lymphoma, lymphoma, t-cell, cutaneous, t-lymphocytes, pharmacokinetics, lymphoma, t-cell | Phase 2 | Recruiting | 2026 |
| Prophylaxis of Recurrent Erysipelas in Lower Limbs compreSsion thErapy vs aNTibiotics and Compression Therapy NCT07549594 — nurses, research design, cellulitis, telemedicine, emollients, erysipelas, penicillin v, therapeutics, random allocation, infections, stockings, compression, male | Phase 4 | Not yet recruiting | 2026 |
LeadR Networks
Main global connection map